Review examines how biology may refine pancreatic cancer surgery decisions
The authors describe established and emerging markers of tumor behavior, while emphasizing that many still need prospective validation before routine clinical use.
Moderate evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Pancreatic ductal adenocarcinoma is often classified as operable or inoperable based on how the tumor appears to contact nearby blood vessels on scans. This review argues that anatomy alone may not fully show how aggressive the disease is or whether cancer has already spread in ways that scans cannot detect.
The authors examined research on “biological resectability,” which adds markers of tumor behavior to imaging-based assessment. They describe carbohydrate antigen 19-9 as the most established marker, while circulating tumor DNA and other approaches remain promising but not ready for routine use based on the evidence summarized.
The question reviewed
The researchers conducted a structured narrative review of contemporary evidence on biological resectability in pancreatic ductal adenocarcinoma. They prioritized consensus statements, clinical practice guidelines, meta-analyses, randomized trials, prospective cohorts, and large multicentre studies, then qualitatively classified biomarkers according to their clinical maturity. The abstract does not state the total number of included studies or patients.
What the evidence shows
The review reports that imaging-based anatomical classifications may not identify hidden systemic disease, early recurrence, or which patients are likely to receive meaningful cancer-related benefit from surgery. It identifies carbohydrate antigen 19-9 as the most clinically established biomarker, with interpretation affected by biliary conditions, response to treatment, and multidisciplinary assessment. Circulating tumor DNA may help with molecular staging and recurrence-risk assessment, but prospective interventional validation remains limited. Transcriptomic subtypes, PET-derived measures, radiomics, and combined biomarker models are described as providing additional biological information but as largely investigational.
Who this may apply to
This review is relevant to people with pancreatic ductal adenocarcinoma because it discusses how imaging findings and biological markers may be considered in treatment planning. However, it does not establish that any particular biomarker improves outcomes, and the findings should not be treated as applying uniformly to every patient.
Why it matters
The review highlights why the appearance of a pancreatic tumor on scans may not provide a complete picture of disease behavior. In principle, combining anatomical information with biological markers could help researchers and clinicians study treatment sequencing and patient selection more precisely. However, this review does not show that biomarker-guided decisions improve survival or other patient outcomes, and it does not establish a routine test strategy. The findings concern human cancer research; no animal or laboratory findings are presented as evidence here, although the review may include studies using different research methods in its cited literature that are not detailed in the abstract.
Limitations & evidence assessment
The review is narrative and qualitatively synthesizes selected studies rather than providing a pooled estimate of effects. The abstract does not report the number or detailed characteristics of included studies, and it does not describe a formal risk-of-bias assessment. The review notes that prospective validation, standardized testing, and biomarker-guided clinical trials are still limited, especially for circulating tumor DNA, molecular subtypes, PET measures, radiomics, and combined models. These limitations mean the findings describe an evolving research area rather than establishing a proven decision rule.
Why this evidence level: This is a structured narrative review that considers guidelines, consensus statements, trials, observational studies, and other research. Because the evidence was synthesized qualitatively rather than through a formal systematic review or meta-analysis, and several biomarkers remain investigational, the overall level is rated moderate rather than high.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Annali Italiani di Chirurgia · 2026 · DOI: 10.62713/aic.4732
This review analyzed human studies comparing two treatments given before surgery for locally advanced esophageal or esophagogastric junction adenocarcinoma: FLOT chemotherapy and CROSS chemoradiotherapy. The pooled estimate favored FLOT for overall survival, but the groups had similar three-year survival, tumor response, surgical margins, and several major perioperative outcomes.
A systematic review examined whether Passiflora edulis, commonly known as passion fruit, is linked with lower blood pressure. It included six preclinical studies and two human trials; the animal and laboratory findings were generally more extensive than the human evidence. The authors reported possible blood-pressure reductions but emphasized that the human studies were small, varied in the extracts used, and short in duration.
Researchers studied 96 people with high-risk, locally advanced rectal cancer in a single-center phase II clinical trial. The treatment combined chemotherapy, short-course radiation, and a targeted drug selected for each study cohort. Overall, 40% had a complete response, but the study did not establish how this approach compares with other treatments.
